Navigation Links
Experimental Drug Offers Hope for Cystic Fibrosis Patients
Date:4/27/2010

Ataluren being tested in humans with several diseases caused by genetic mutations

TUESDAY, April 27 (HealthDay News) -- An experimental oral drug called ataluren may treat cystic fibrosis and other diseases caused by genetic "nonsense mutations," U.S. researchers report.

Nonsense mutations disrupt the way cells make proteins. About one-third of gene defects linked to human disease are believed to come from nonsense mutations, and ataluren holds promise for treating more than 2,400 such disorders, the study authors noted.

In cystic fibrosis, the lack of a certain protein results in an imbalance of salt and water in the linings of the lungs and other membranes. In this new study, researchers found that ataluren allowed the protein to be made in mouse cells where it was previously absent, which helped restore normal salt and water balance.

"When you treat a genetic disease, the bottom line is how much of the missing protein do you need to restore to have a therapeutic benefit," researcher David Bedwell, a professor in the microbiology department at the University of Alabama at Birmingham, said in a university news release.

"It comes down to the threshold of protein rescue. For some diseases, it might be 1 percent of protein you need restored, and for other diseases you may need 50 percent of protein restored," he explained.

Bedwell found that ataluren can restore up to 29 percent of normal protein function in mice with cystic fibrosis. The research, funded by PTC Therapeutics Inc., was presented April 26 at the Experimental Biology 2010 conference in Anaheim, Calif.

Ataluren is now being tested in humans with cystic fibrosis, hemophilia A, hemophilia B, Duchenne/Becker muscular dystrophy and other conditions.

More information

The Cystic Fibrosis Foundation has more about cystic fibrosis.



-- Robert Preidt



SOURCE: University of Alabama at Birmingham, news release, April 26, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Experimental stem cell treatment arrests acute lung injury in mice, study shows
2. RetiringbyDesign.com Offers Retirees a Smarter Way to Explore Living Options
3. Ovarian cancer study offers vital clues for new therapies
4. American Laser Centers Offers a Solution for Customers Whose Laser Cosmetic Providers Have Gone Out of Business
5. TotalTrans4m Offers Natural Product Just in Time for Wedding Season That Can Jump Start Weight Loss
6. Newly Relaunched Autoinsurance.net Offers Consumers Smart Tips To Consider When Purchasing Car Insurance
7. S.A. Lifeline Foundation Offers New and Improved Website for Those with Pornography Addictions
8. Arsa Offers High Quality Supplements, Cosmetics and Magic Scents from Mexico for Less Than $10
9. Study Offers Insights Into Male Pattern Baldness
10. SEO-Peace.com Extends The March Special SEO Special Offers And Revise Many Services
11. UNC study offers first clinical evidence of anti-cancer drug triggering viral infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne ... signature product of her research center at Bio-Logic Aqua Research® Water Life Science®, ... the greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... may give insight into why concussion rates are on the rise, say researchers ... Annual Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... enterprise-grade IT operations analytics and application performance monitoring (APM) solutions, has expanded ... healthcare services providers. , According to Peter Ohrenberger, sales director at Nastel, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a ... for everyone affected by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon ... off on July 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s ...
(Date:7/20/2017)... ... July 20, 2017 , ... Using CDRH’s Medical Device ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          , Device makers ... It’s known as the “CY2016 Annual FDA Medical Device Quality System Data” report. ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... division of Diplomat Specialty Infusion Group, is celebrating a decade of empowering ... celebrate its anniversary, ThriveRx recently launched a redesigned website at thriverx.diplomat.is ... to create the best user experience for consumers and health care professionals. ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 years," ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology: